CNBS

Amplify Seymour Cannabis ETF

As of 3/31/25

FUND FACTS

Ticker	CNBS
CUSIP	032108482
Launch Date	07/23/2019
Primary Exchange	NYSE ARCA
Number of Holdings	30

FEES & EXPENSES

Management Fee	0.65%
Other Expenses	0.68%
Acquired Fund Fees & Expenses	0.01%
Total Expense Ratio	1.34%
Less Fee Waiver/Reimbursement*	0.58%
Net Expense Ratio	0.76%

PORTFOLIO MANAGEMENT



Tim Seymour Seymour Asset Management LLC

MARKET CAPITALIZATION

Large Cap (> \$10B)	0.00%
Mid Cap (\$2B - \$10B)	0.00%
Small Cap (< \$2B)	100%

OBJECTIVE AND STRATEGY

CNBS is an actively managed ETF that provides diversified U.S. exposure across the cannabis ecosystem including cannabis: plants, support, and ancillary businesses. CNBS seeks to provide capital appreciation.

REASONS TO INVEST

- (1) Green Rush Growth Potential: In the U.S., sales of legal recreational cannabis are expected to grow from \$32.1 billion in 2024 to reach nearly \$58 billion by 2030.¹
- (2) Active Management: Allows for timely decisions in this dynamic space. Tim Seymour is an experienced investor and recognized voice in the cannabis sector.
- (3) **Convenient Access:** Through a single ETF, gain convenient access to a basket of companies across the cannabis and hemp ecosystem.

TOP 10 HOLDINGS

TICKER	COMPANY	% WT.	TICKER	COMPANY	% WT.
GTII CN	Green Thumb Industries SWAF	°14.05%	VRNO CN	Verano Hldgs SWAP	5.20%
TRUL CN	Trulieve Cannabis SWAP	9.60%	TSND CN	TerrAscend	4.89%
CURA CN	Curaleaf Holdings	8.63%	MAPS	WM Technology	4.55%
CRLBF	Cresco Labs SWAP	8.25%	IIPR	Innovative Industrial Properties	3.07%
GLASF	Glass House Brands SWAP	6.20%	GTII CN	Green Thumb Industries SWAP	2.09%

Holdings and allocations are subject to change at any time and should not be considered a recommendation to buy or sell a security.

PERFORMANCE	CUMULATIVE (%)			ANNUALIZED (%)			
	1 MO.	YTD	SINCE INCEPTION	1 YR.	3 YR.	5 YR.	SINCE INCEPTION
NAV	-13.82%	-28.64%	-91.43%	-63.86%	-44.95%	-24.79%	-35.05%
Closing Price	-13.93%	-31.26%	-91.72%	-64.94%	-45.56%	-25.32%	-35.44%

Fund inception date: 07/22/2019. The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted. For the most recent month-end performance, visit AmplifyETFs.com/CNBS. Brokerage commissions will reduce returns. NAV is the sum of all its assets less any liabilities, divided by the number of shares outstanding. The closing price is the last price at which the fund traded.



- MSO (64.82%)
- Cultivation & Retail (22.62%)
- Investing & Finance (6.34%)
- Real Estate (4.48%)
- Agricultural Technology (1.62%)
- Hemp Products (0.12%)

ACTIVE MANAGEMENT SELECTION PROCESS

CNBS invests at least 80% of its assets in securities of U.S. companies that derive 50% or more of their revenue from the cannabis and hemp ecosystem, across one of three classifications:

Cannabis/Hemp Plant

- Pharma/BioTech
- Cultivation & Retail
- Hemp Products
- Cannabis-infused Products

Support

- Agricultural Tech
- Real Estate
- Commercial Services

Ancillary

- Consumption Devices
- Investing & Finance
- Tech & Media

Carefully consider the Fund's investment objectives, risks, charges, and expenses before investing. This and other information can be found in the Fund's statutory and summary prospectuses, which may be obtained at amplifyetfs.com. Read the prospectus carefully before investing.

Investing involves risk, including the possible loss of principal. The Fund is subject to management risk because it is an actively managed. Companies involved in the cannabis industry face competition, may have limited access to the services of banks, may have substantial burdens on company resources due to litigation, complaints or enforcement actions, and are heavily dependent on receiving necessary permits and authorizations to engage in medical cannabis research or to otherwise cultivate, possess or distribute cannabis. The possession and use of cannabis, even for medical purposes, is illegal under federal and certain states' laws, which may negatively impact the value of the Fund's investments. Securities issued by non-U.S. companies present risks beyond those of securities of U.S. issuers.

Many of the companies in which the Fund will invest are engaged in other lines of business unrelated to cannabis and these lines of business could adversely affect their operating results. Cannabis is a Schedule I controlled substance under the Controlled Substances Act ("CSA"), meaning that it has a high potential for abuse, has no currently "accepted medical use" in the U.S., lacks accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the U.S. Small and/or mid-capitalization companies may be more vulnerable to adverse general market or economic developments, and their securities may be less liquid and may experience greater price volatility than larger, more established companies as a result of several factors, including limited trading volumes, products or financial resources, management inexperience and less publicly available information. The Fund is non-diversified, which can cause greater share price fluctuation.

Amplify Investments LLC is the Investment Adviser to the Fund. Seymour Asset Management LLC and Tidal Financial LLC serve as the Investment Sub-Advisers. Amplify ETFs are distributed by Foreside Fund Services, LLC.

*The Fund's investment adviser has contractually agreed to waive its advisory fees and/or assume as its own expense certain expenses otherwise payable by the Fund to the extent necessary to ensure that total annual fund operating expenses do not exceed 0.75% of average daily net assets until March 1, 2026.

¹https://www.statista.com/markets/415/topic/2436 cannabis/#statistic1

Not FDIC Insured | No Bank Guarantee | May Lose Value